<DOC>
	<DOCNO>NCT01540760</DOCNO>
	<brief_summary>This single-center , randomize , placebo-controlled , double-blind , multiple ascend dose study evaluate safety , pharmacokinetics immunogenicity MCAF5352A healthy volunteer . Subjects randomize receive either MCAF5352A placebo Days 1 , 15 29 .</brief_summary>
	<brief_title>A Study MCAF5352A Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female , 18 55 year age Subjects good health determine screen medical history , physical examination , vital sign , 12lead ECG laboratory test Body weight 45 kg 110 kg Female subject must willing use two effective method contraception screen minimum 4 month last dose study drug Pregnant lactate woman Positive hepatitis B , hepatitis C HIV infection History significant chronic recurrent infection History clinically significant drug allergy and/or know hypersensitivity protein therapeutic formulation component related drug History alcohol drug abuse within 12 month prior Day 1 , evidence abuse Subjects previously receive study drug Participation clinical trial within 4 week prior Day 1 use experimental biologic therapy within 12 week prior Day 1 within 5 halflives product , whichever great</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>